This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Endocarditis and Heart Valve Disorders in Diseases Classified Elsewhere달리 분류된 질환에서의 심내막염 및 심장판막장애 (타분류질환의 심내막염 및 심장판막장애)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I39 (Endocarditis and heart valve disorders in diseases classified elsewhere) | Special Copayment Reduction: V192 (Special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsLibman-Sacks endocarditis, nonbacterial thrombotic endocarditis (NBTE), carcinoid heart disease, marantic endocarditis, Lupus endocarditis
C. Adult onsetA form in which heart valve involvement appears during the course of an underlying systemic disease (SLE, antiphospholipid antibody syndrome, carcinoid, malignancy, Whipple's disease); it occurs across adulthood, and its presentation varies with the prevalence of the underlying disease.
1. HistoryLibman and Sacks described nonbacterial endocarditis in 1924; discovery of antiphospholipid antibody syndrome and establishment of its association with Libman-Sacks
2. CausesSLE and APS (Libman-Sacks), carcinoid syndrome, malignancy (marantic endocarditis), Whipple's disease, after radiation therapy
3. GeneticsAssociation of SLE with HLA-DR3 and DR2; APS with HLA-DQ8 and DR7; MEN-1 syndrome and carcinoid; tumor-related genes such as TRP53
4. General epidemiologyValve abnormalities in about 10–50% of SLE patients; carcinoid heart disease occurs in about 50% of carcinoid syndrome
5. PathophysiologyValvular endothelial injury by immune complexes and autoantibodies (Libman-Sacks); valvular fibrosis by serotonin and substance P (carcinoid)
6. SymptomsMostly asymptomatic and found incidentally; embolism (cerebral infarction, peripheral embolism); heart failure symptoms from valve regurgitation or stenosis
7. SignsValve murmurs (regurgitation, stenosis); signs of the underlying systemic disease (butterfly rash, facial flushing, diarrhea, right heart failure, etc.)
8. ScreeningEchocardiography at diagnosis of the underlying disease and at regular follow-up; regular valve evaluation in patients with SLE, APS, or carcinoid syndrome
9. DiagnosisEchocardiography (TTE/TEE), antiphospholipid antibody testing, 5-HIAA (carcinoid), blood cultures (to exclude infective endocarditis)
10. TreatmentTreatment of the underlying disease (immunosuppressants, anticoagulants); surgical valve surgery for severe valve dysfunction; anticoagulation (embolism prevention)
11. PrognosisProgression of valve lesions varies with control of the underlying disease; carcinoid heart disease is one of the factors that most worsen prognosis
12. PreventionActive control of the underlying disease; anticoagulation in SLE and APS; serotonin suppression with somatostatin analogues in carcinoid
13. ReferencesLibman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis … and 9 other papers

1. History

Endocarditis and heart valve disorders accompanying diseases classified elsewhere are among the most important forms of cardiac involvement by underlying systemic diseases. The historical milestone in this field began with the 1924 publication by Emanuel Libman and Benjamin Sacks. These two physicians at Mount Sinai Hospital in New York described, in four patients, an unusual form of endocarditis in which small sterile vegetations formed on the valves (mainly the mitral and aortic valves) without evidence of infection, and this lesion later came to be called "Libman-Sacks endocarditis" after them.

Initially the cause of Libman-Sacks endocarditis was unclear, but in the 1950s–60s a strong association with systemic lupus erythematosus (SLE) was established. In pathological anatomy studies of SLE, Libman-Sacks lesions were found in about 50% of patients who died of SLE, which first demonstrated the importance of valve damage by autoimmune mechanisms. In the 1980s–90s, as the concept of antiphospholipid antibody syndrome (APS) was established, Libman-Sacks lesions were also found to be strongly associated with APS.

Carcinoid heart disease was first described pathologically by Hedinger in 1954, after which the valvular toxic effects of serotonin and other vasoactive amines were elucidated. Nonbacterial thrombotic endocarditis (NBTE, marantic endocarditis) was gradually recognized to be associated with malignancy, sepsis, and wasting diseases, and became established as an important cause of asymptomatic embolism. Valve involvement in Whipple's disease was systematized through observational studies from the 1980s onward, and it is now approached with PCR diagnosis for Tropheryma whipplei and antibiotic treatment.


2. Causes

The causes of endocarditis and heart valve disorders classified under ICD I39 are based on various underlying systemic diseases. The most important causative diseases are as follows.

Libman-Sacks endocarditis in systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome (APS) is characterized by nonbacterial thrombotic vegetations forming on the valves (especially the atrial side of the posterior mitral leaflet and the aortic valve). The vegetations are mostly small and flat and can occur on both the atrial surface (lower surface) and the ventricular surface (upper surface) of the valve leaflets. Echocardiographic abnormalities are found in about 50% of SLE patients, and actual Libman-Sacks lesions are observed in about 10–15% of them.

Cardiac involvement in carcinoid syndrome (carcinoid heart disease) mainly affects the right heart valves (tricuspid and pulmonary valves). Serotonin, substance P, and other vasoactive amines not inactivated in the liver directly stimulate the right heart endocardium, forming fibrous plaques on the valve leaflets and endocardium. Marantic endocarditis (NBTE) accompanying malignancy (especially metastatic adenocarcinoma) forms small sterile thrombi on the valves and causes cerebral and systemic embolism. Whipple's disease rarely involves the heart valves through Tropheryma whipplei infection, and vegetations and valve regurgitation are observed on echocardiography.


3. Genetics

For endocarditis and valve disorders in diseases classified elsewhere, the genetic background of the underlying disease is key. The genetic predisposition to systemic lupus erythematosus (SLE) is complex and polygenic, and HLA-DR3, HLA-DR2, HLA-DQ1, and others are associated with disease susceptibility. Complement component deficiencies (C1q, C2, C4 deficiency) are strong genetic risk factors for SLE, and in particular C1q deficiency appears in more than 90% of SLE. Variants in interferon signaling pathway genes such as TREX1, RNASEH2A-C, SAMHD1, ADAR, and IFIH1 are also related to SLE susceptibility.

Antiphospholipid antibody syndrome (APS) is mainly an acquired disease, and its genetic background partly overlaps with that of SLE. HLA-DQ7, HLA-DQ8, HLA-DR7, and others are associated with antiphospholipid antibody formation. For the genetic background of carcinoid tumors, multiple endocrine neoplasia type 1 (MEN-1, MEN1 gene variants) is important, and about 5% of small intestinal carcinoids are related to MEN-1. CDKN1B (p27) variants have also been reported in small intestinal neuroendocrine tumors. Susceptibility to Whipple's disease is known to be associated with HLA-B27 positivity and certain immunodeficiencies (reduced CD4+ T cell function).


4. General epidemiology

The epidemiology of endocarditis and valve disorders under code I39 is determined by the epidemiology of each underlying disease. The incidence of echocardiographic abnormalities in SLE patients is about 30–50%, and clinically significant Libman-Sacks endocarditis is observed in about 10–15%. Mitral regurgitation is the most common, followed by the aortic and tricuspid valves. The incidence of cardio-cerebrovascular embolism in patients with SLE and APS is significantly higher than in the general population, and some of these are presumed to be due to embolism from Libman-Sacks vegetations.

Carcinoid heart disease occurs in about 40–50% of patients with metastatic carcinoid syndrome and is characterized by tricuspid regurgitation with pulmonary valve stenosis or regurgitation. The development of carcinoid heart disease is an independent factor that significantly worsens the prognosis of patients with carcinoid syndrome. The exact prevalence of marantic endocarditis is unclear, but it is found in about 1–5% in autopsy studies of patients with malignancy. It should always be considered in the differential diagnosis of patients with malignancy who develop cerebral infarction.


5. Pathophysiology

The pathophysiology of Libman-Sacks endocarditis combines autoimmune and thrombotic mechanisms. In SLE and APS, autoantibodies (antiphospholipid antibodies, anti-beta-2 GPI antibodies, anticardiolipin antibodies) bind to phospholipid-binding proteins (beta-2 GPI, annexin V) on the surface of valvular endothelial cells, activating and damaging the endothelial cells. Platelets and fibrin deposit on the damaged endothelial surface, forming nonbacterial vegetations (NBTE). In this process, local immune complex deposition, complement activation, and cytokine secretion contribute to vegetation formation and valve tissue damage. With chronicity, organization and fibrosis of the vegetations progress, causing thickening, deformity, and regurgitation of the valve leaflets.

In carcinoid heart disease, serotonin (5-HT) and other vasoactive amines not inactivated in the liver act directly on the right heart endocardium. Serotonin activates cardiac myofibroblasts via the 5-HT2B receptor and, through TGF-β signaling, induces extracellular matrix remodeling and fibrous thickening of the valve leaflets (plaque formation). This mechanism shares the same 5-HT2B pathway as valve disease associated with appetite suppressants (fenfluramine). In marantic endocarditis, systemic hypercoagulability (including DIC) and excessive cytokine secretion due to malignancy or sepsis form the basis of nonbacterial vegetation formation.


6. Symptoms

Endocarditis and valve disorders in diseases classified elsewhere are mostly asymptomatic initially and are often found incidentally on follow-up echocardiography for the underlying disease. When symptoms appear, they take two main forms.

The first is embolic symptoms. Emboli from Libman-Sacks lesions or NBTE vegetations cause cerebral infarction (aphasia, hemiplegia, altered consciousness), retinal artery occlusion (visual field defects), renal infarction (flank pain, hematuria), splenic infarction (left upper abdominal pain), peripheral arterial occlusion (limb pain, cyanosis), and others. When recurrent stroke occurs in SLE patients or antiphospholipid antibody syndrome is present, Libman-Sacks should be ruled out first. The second is heart failure symptoms from valve dysfunction. As severe valve regurgitation (mainly mitral regurgitation) progresses, exertional dyspnea, orthopnea, and fatigue appear. In carcinoid heart disease, right heart failure symptoms (lower limb edema, ascites, fatigue) are prominent and are a major factor determining the prognosis of patients with metastatic carcinoid syndrome.


7. Signs

Physical examination findings of Libman-Sacks endocarditis appear together with the systemic signs of the underlying SLE or APS. As a cardiac sign, a systolic murmur due to valve regurgitation (mainly mitral regurgitation) may be observed, but the vegetations themselves are small and often do not cause a murmur. Systemic signs of SLE (butterfly facial rash, photosensitivity, arthritis, oral ulcers) accompany it.

In carcinoid heart disease, a tricuspid regurgitation murmur (systolic murmur) and a pulmonary stenosis murmur (systolic ejection murmur) are heard together with signs of right heart failure (elevated jugular venous pressure, pulsatile hepatomegaly, lower limb edema, ascites). Systemic signs of carcinoid syndrome (facial flushing, diarrhea, bronchospasm) accompany it. In marantic endocarditis, evidence of multiple emboli (retinal hemorrhage, focal neurological deficits, cyanotic fingers and toes) may appear together with signs of the underlying malignancy.


8. Screening

For endocarditis and valve disorders in diseases classified elsewhere, regular echocardiographic screening in patients with the underlying disease is the key screening method. In patients diagnosed with SLE, baseline echocardiography is performed at initial diagnosis, and follow-up examinations are then performed according to the clinical situation (accompanying APS, palpitations, dyspnea, suspected embolism). In antiphospholipid antibody–positive patients, the occurrence of thrombosis and the presence of valve abnormalities are evaluated regularly.

In patients diagnosed with carcinoid syndrome, echocardiography is performed at diagnosis to evaluate cardiac involvement, and serum or urinary 5-HIAA (5-hydroxyindoleacetic acid) levels are measured as well. Early detection of carcinoid heart disease is important for determining the timing of surgical treatment. In patients with malignancy, especially those with adenocarcinoma or hormone-secreting tumors, echocardiography and differentiation of NBTE should be considered when an embolic event occurs.


9. Diagnosis

Diagnosis is made by combining confirmation of the underlying disease with echocardiographic findings. Transthoracic echocardiography (TTE) is the first-line test for evaluating the size and location of vegetations and the severity of valve regurgitation or stenosis. Libman-Sacks vegetations are observed via the transthoracic approach as small, flat echogenic lesions attached to the middle or basal portion of the valve leaflets. Infective endocarditis vegetations are larger, more mobile, and accompanied by destructive changes, whereas Libman-Sacks vegetations are relatively small and regular.

Transesophageal echocardiography (TEE) is superior for precisely characterizing vegetations and is needed especially to evaluate lesions not clearly seen on TTE. Blood cultures must be performed to differentiate from infective endocarditis, and antiphospholipid antibody testing (anticardiolipin antibodies, anti-beta-2 GPI, lupus anticoagulant) is performed for the diagnosis of SLE and APS. For the diagnosis of carcinoid, measurement of serum CgA and urinary 5-HIAA and imaging (abdominal and chest CT, Ga-DOTATATE PET) are needed. When Whipple's disease is suspected, small bowel biopsy with PAS staining and Tropheryma whipplei PCR are performed.


10. Treatment

Treatment of endocarditis and valve disorders in diseases classified elsewhere centers on treatment of the underlying disease. In Libman-Sacks endocarditis associated with SLE and APS, immunosuppressive treatment to control the underlying autoimmune disease (hydroxychloroquine, corticosteroids, azathioprine, belimumab, etc.) takes priority. When antiphospholipid antibody positivity or APS is confirmed, anticoagulation (warfarin, DOAC) is recommended to prevent thrombosis and embolism. When severe valve regurgitation develops, surgical valve repair or replacement is considered, but because of the risk of postoperative recurrence, the control status of the underlying autoimmune disease must also be evaluated.

In carcinoid heart disease, suppression of serotonin secretion with somatostatin analogues (octreotide, lanreotide) can slow lesion progression. Because the risk of complications from cardiac surgery is high in patients with a high carcinoid burden (elevated 5-HIAA), reducing the tumor burden before surgery is recommended. When there is severe tricuspid regurgitation or pulmonary valve stenosis and the patient's condition permits, tricuspid and pulmonary valve replacement is recommended. In Whipple's disease, long-term antibiotic treatment is given with TMP-SMX, or ceftriaxone followed by a switch to TMP-SMX. In marantic endocarditis, anticoagulation is considered together with treatment of the underlying malignancy.


11. Prognosis

The prognosis of endocarditis and valve disorders in diseases classified elsewhere is determined by the severity of the underlying disease and the degree of valve dysfunction. In SLE patients, Libman-Sacks endocarditis increases the risk of cerebrovascular embolism, and the risk of recurrent cerebral infarction is even higher when APS is present. Appropriate immunosuppression and anticoagulation can reduce the risk of embolism, but valve dysfunction itself tends to progress slowly.

Carcinoid heart disease is an independent prognostic factor that significantly worsens the prognosis of patients with metastatic carcinoid syndrome. The median survival of patients with carcinoid heart disease is shortened to about half that of patients without it. Valve surgery at the appropriate time contributes to symptom improvement and better survival, but management of the risk of carcinoid crisis due to anesthesia and surgical stress is needed during surgery. In marantic endocarditis, the prognosis of the underlying malignancy determines the overall prognosis, and embolic complications such as cerebral infarction greatly reduce quality of life.


12. Prevention

The key to preventing endocarditis and valve disorders in diseases classified elsewhere is early diagnosis and active treatment of the underlying disease. In SLE patients, observational studies suggest that continued immunosuppressive treatment to minimize disease activity and maintenance of an antimalarial (hydroxychloroquine) may reduce the development and progression of valve lesions. In APS, embolic complications are prevented with appropriate anticoagulation.

To prevent and suppress the progression of carcinoid heart disease, suppression of vasoactive amine secretion with somatostatin analogues and reduction of tumor burden (resection, radiofrequency ablation, hepatic artery embolization, peptide receptor radionuclide therapy) are important. Studies have shown that keeping 5-HIAA levels low reduces the development and progression of carcinoid heart disease. For all patients diagnosed with carcinoid syndrome, early detection of cardiac involvement through regular echocardiographic follow-up so as not to miss the optimal timing for surgery is preventively important.


13. References

  1. Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Archives of Internal Medicine. 1924;33(6):701-737. DOI: 10.1001/archinte.1924.00110300044002.

  2. Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. New England Journal of Medicine. 1996;335(19):1424-1430. DOI: 10.1056/NEJM199611073351903. PMID: 8875919.

  3. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996;93(8):1579-1587. DOI: 10.1161/01.CIR.93.8.1579. PMID: 8608627.

  4. Moyssakis I, Tektonidou MG, Vasilliou VA, et al. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. American Journal of Medicine. 2007;120(7):636-642. DOI: 10.1016/j.amjmed.2007.01.024. PMID: 17602938.

  5. Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. American Journal of Cardiology. 2008;101(3):378-381. DOI: 10.1016/j.amjcard.2007.08.045. PMID: 18237607.

  6. Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart. 2004;90(10):1224-1228. DOI: 10.1136/hrt.2004.040329. PMID: 15367531.

  7. Dimmock NJ, Easton AJ, Leppard KN. Introduction to Modern Virology. (Related: Rogers AM, Thomas L. Marantic endocarditis and cancer: a systematic review.) Journal of Thrombosis and Thrombolysis. 2019;48(1):18-28. DOI: 10.1007/s11239-019-01848-9. PMID: 30953215.

  8. Mzabi A, Asmi M, Kechrid C, et al. Heart valve disease in systemic lupus erythematosus, role of antiphospholipid antibodies. Journal of Cardiology. 2016;67(6):559-563. DOI: 10.1016/j.jjcc.2015.06.013. PMID: 26265393.

  9. Castrejón I, Roces-Varela J, Campos C, et al. Valvular heart disease in patients with antiphospholipid syndrome. Lupus. 2019;28(6):725-735. DOI: 10.1177/0961203319838783. PMID: 30879373.

  10. Connolly HM, Nishimura RA, Smith HC, Pellikka PA, Mullany CJ, Kvols LK. Outcome of cardiac surgery for carcinoid heart disease. Journal of the American College of Cardiology. 1995;25(2):410-416. DOI: 10.1016/0735-1097(94)00386-J. PMID: 7829793.